AKT1 and B-cell chronic lymphocytic leukemia: All patient samples showed reduced Akt (pS473) levels after treatment with increasing concentrations of the drug (Figure 4D), demonstrating that pathway inhibitors can be applied to normalize aberrant signaling in CLL cells.